SPRY — ARS Pharmaceuticals Income Statement
0.000.00%
- $824.58m
- $600.95m
- $0.03m
- 45
- 10
- 80
- 41
Annual income statement for ARS Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 1.32 | 0.03 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 24.1 | 32.9 | 89.6 | 36.8 | 67.5 |
Operating Profit | -24.1 | -32.9 | -89.6 | -35.5 | -67.5 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -24 | -32.9 | -89.5 | -34.7 | -54.4 |
Net Income After Taxes | -24 | -32.9 | -89.5 | -34.7 | -54.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -24 | -32.9 | -89.5 | -34.7 | -54.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -24 | -32.9 | -89.5 | -34.7 | -54.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.725 | -0.949 | -2.56 | -0.868 | -0.571 |
Dividends per Share |